期刊文献+

骨形成蛋白-2通过JNK信号通路促进肝癌HepG2细胞凋亡 被引量:2

BMP-2 Induces Apoptosis of Human Hepatocellular Carcinoma Cell HepG2 via JNK Signaling Pathway
原文传递
导出
摘要 目的观察骨形成蛋白-2(bone morphogenetic protein-2,BMP-2)对人肝癌HepG-2细胞凋亡的作用及其信号通路机制。方法用流式细胞分析和细胞凋亡ELISA法检测HepG2细胞凋亡,用Western blot法检测丝裂原激活蛋白激酶(MAPKs)和磷脂酰肌醇3-激酶(PI3K)下游效应因子Akt的激活,采用信号通路阻断剂预处理HepG2细胞观察BMP-2影响细胞凋亡的机制。结果BMP-2诱导HepG2细胞凋亡,呈时间和剂量依赖性;BMP-2激活HepG2细胞JNK激酶,但不能激活ERK1/2、p38及Akt;采用JNK信号通路抑制剂SP600125可阻断BMP-2对HepG-2细胞JNK的激活,并消除BMP-2对HepG-2细胞凋亡的作用。结论BMP-2通过JNK信号通路途径诱导HepG2肝癌细胞凋亡。 Objective To characterize the effect of BMP- 2 on apoptosis of human hepatocellular carcinoma cell HepG2 and the signaling pathway involved in it. Methods Cell apoptosis was assessed by flow cytometry and ELISA. Western blot was used to show the activation of MAPKs (ERK1/2, JNK and p38) and Akt. A specific JNK inhibitor SP600125 was used for the signaling pathway study. Results BMP - 2 dose - and time - dependent effects induced HepG2 cells apoptosis. BMP - 2 induced JNK activation in HepG2 cells. SP600125 abolished the effects of BMP - 2 on JNK activation and apoptosis in HepG2 cells. Conclusions The present study suggests that BMP- 2 induces HepG2 cells apoptosis through JNK signaling pathway.
作者 刘浒 唐四元
出处 《实用预防医学》 CAS 2009年第4期1021-1024,共4页 Practical Preventive Medicine
基金 湖南省自然科学基金(05C0163) 湖南省博士后科研专项计划项目(2008RS4012)
关键词 骨形成蛋白-2 JNK 肝癌细胞 凋亡 Bone morphogenetic protein-2 JNK Hepatocellular carcinoma cell Apoptosis
  • 相关文献

参考文献2

二级参考文献8

共引文献8

同被引文献21

  • 1Bao-GangPeng Li-JiangLiang QiangHe MingKuang Jia-MingLia Ming-DeLu Jie-FuHuang.Tumor vaccine against recurrence of hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(5):700-704. 被引量:28
  • 2Morales A, Eidingcr D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors[J]. J Uro, 1976,116 (2):180-183.
  • 3Pogiela T, Kulig J, Czupryna A, et al. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer[J], Gastric Cancer, 2004,7(4):240-245.
  • 4Verrnorken JB, Claessen AM, Van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial[J]. Lancet, 1999, 353(9150):345-350.
  • 5Belisle JT, Vissa VD, Sievert T,et al.Role of the major antigen of Mycobaeterium tuberculosis in cell wall biogenesis [J].Science, 1997,276:1420-1422.
  • 6Britton WJ, Palendira U. Improving vaccines against tuberculosis[J]. Immunology and cell biology, 2003, 81(1):34-35.
  • 7Starck J, Kallenius G, Marklund BI, et al. Comparative proteome analysis of Mycobacterium tuberculosis grown under aerobic and anaerobic conditions[J]. Microbiology, 2004, 150( 11):3821-3829.
  • 8Kaasinen ES, Harju LM, Alfthan OS, et al. Non-specific, rapidly generated cytotoxicity in lymphocytes induced by BCG in vitro: no evidence of enhancing effect from preceding interaction between BCG and transitional cell line cells[J]. J Uro, 2000,163(1):317-322.
  • 9Zlotta AR, van Vooren JP, Huygen K, et al. What is the optimal regimen for BCG intravesical therapy Are six weekly instillations necessary [J]. Eur Uro, 2000,37(4):470-477.
  • 10Amling CL. Diagnosis and management of superficial bladder cancer [J], Curr Prob Cancer, 2001,25(4):219-278.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部